1. Catalog
  2. Nodes
  3. bp(GO:"retrograde axonal transport")

bp(GO:"retrograde axonal transport")

Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Entity

Name
retrograde axonal transport
Namespace
go
Namespace Version
20180921
Namespace URL
https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns

Appears in Networks 2

Analysis of Isoform-specific Tau Aggregates Suggests a Common Toxic Mechanism Involving Similar Pathological Conformations and Axonal Transport Inhibition v1.0.1

Tau in physiology and pathology v1.0.0

In-Edges 7

p(HBP:"Tau isoform B (381 aa)", pmod(HBP:"protein aggregation")) causesNoChange bp(GO:"retrograde axonal transport") View Subject | View Object

hT40, hT34, hT24, hT37 and hT23 aggregates did not significantly impair retrograde FAT when compared to the respective monomers, but hT39 aggregates elicited a mild inhibitory effect on retrograde FAT (Fig. 4B) PubMed:27574109

Appears in Networks:

p(HBP:"Tau isoform C (410 aa)", pmod(HBP:"protein aggregation")) decreases bp(GO:"retrograde axonal transport") View Subject | View Object

hT40, hT34, hT24, hT37 and hT23 aggregates did not significantly impair retrograde FAT when compared to the respective monomers, but hT39 aggregates elicited a mild inhibitory effect on retrograde FAT (Fig. 4B) PubMed:27574109

Appears in Networks:

p(HBP:"Tau isoform D (383 aa)", pmod(HBP:"protein aggregation")) causesNoChange bp(GO:"retrograde axonal transport") View Subject | View Object

hT40, hT34, hT24, hT37 and hT23 aggregates did not significantly impair retrograde FAT when compared to the respective monomers, but hT39 aggregates elicited a mild inhibitory effect on retrograde FAT (Fig. 4B) PubMed:27574109

Appears in Networks:

p(HBP:"Tau isoform E (412 aa)", pmod(HBP:"protein aggregation")) causesNoChange bp(GO:"retrograde axonal transport") View Subject | View Object

hT40, hT34, hT24, hT37 and hT23 aggregates did not significantly impair retrograde FAT when compared to the respective monomers, but hT39 aggregates elicited a mild inhibitory effect on retrograde FAT (Fig. 4B) PubMed:27574109

Appears in Networks:

p(HBP:"Tau isoform F (441 aa)", pmod(HBP:"protein aggregation")) causesNoChange bp(GO:"retrograde axonal transport") View Subject | View Object

hT40, hT34, hT24, hT37 and hT23 aggregates did not significantly impair retrograde FAT when compared to the respective monomers, but hT39 aggregates elicited a mild inhibitory effect on retrograde FAT (Fig. 4B) PubMed:27574109

Appears in Networks:

p(HBP:"Tau isoform Fetal-tau (352 aa)", pmod(HBP:"protein aggregation")) causesNoChange bp(GO:"retrograde axonal transport") View Subject | View Object

hT40, hT34, hT24, hT37 and hT23 aggregates did not significantly impair retrograde FAT when compared to the respective monomers, but hT39 aggregates elicited a mild inhibitory effect on retrograde FAT (Fig. 4B) PubMed:27574109

Appears in Networks:

p(HGNC:MAPT) decreases bp(GO:"retrograde axonal transport") View Subject | View Object

First, tau competes with kinesin or dynein motors for binding to microtubules, reducing the binding frequency, motile fraction and run length of kinesin and dynein (without changing the motor velocity of kinesin and dynein), and thereby slowing down both anterograde and retrograde transport PubMed:26631930

Appears in Networks:

Out-Edges 0

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.